pharmaphorum

JUNE 2, 2021

Capacity to supply Moderna’s COVID-19 vaccine in Europe could be swelled by round 300 million doses a year, following an agreement to set up a new production line at contract manufacturer Lonza. Full approval means it could be used routinely in future as an annual booster, much like the seasonal influenza vaccine.

Vaccination 52

Vaccination Vaccine Contract Manufacturing Production 52

The Pharma Data

NOVEMBER 17, 2021

Pfizer has begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker. It has entered into advance purchase agreements with several countries and has initiated bilateral outreach to roughly 100 countries around the world.

HR 52

HR Manufacturing Contract Manufacturing Licensing 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Making new and better medicines for humans and animals is at the heart of what we do. About Boehringer Ingelheim.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

The Pharma Data

MARCH 22, 2022

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

The Pharma Data

NOVEMBER 19, 2021

Pfizer has also begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker, including exploring implicit contract manufacturing options.

HR 52

HR Contract Manufacturing Manufacturing Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania. About INOVIO’s DNA Medicines Platform. INOVIO’s DNA medicines do not interfere with or change in any way an individual’s own DNA.

DNA 40

DNA Vaccination Vaccine Immune Response 40

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . billion, compared to $19.9 million price point per dose. Cancer is king .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

JULY 21, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Manufacturing 52

Manufacturing Vaccination Vaccine Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent, recommending to extend the approval in the EU to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for systemic therapy. Oncology Program. 50% PD-L1 expression.

Sales 52

Sales Production Manufacturing Antibody 52

Roots Analysis

FEBRUARY 15, 2022

However, several ADC developers do not have the in-house capabilities to manufacture cytotoxic payload on a commercial scale and tend to rely on contract manufacturers. As per the estimates, 70-80% of ADC manufacturing operations are outsourced. Increased Partnership Activity. Our Social Media Platform. Web: [link].

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52

pharmaphorum

NOVEMBER 12, 2020

Earlier this year, UCB also bought a 47-acre UK R&D campus from Eli Lilly, saying it intends to develop it as a hub for R&D in “gene therapies, translational medicine and antibody discovery.”.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

The Pharma Data

JANUARY 27, 2021

MultiStem ® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. 28, 2021 11:00 UTC. About MultiStem ®.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

Drug Discovery World

FEBRUARY 26, 2024

For example, Vertex Pharmaceuticals’ stem-cell treatment for sickle-cell disease and transfusion-dependent β-thalassemia was authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) in November 2023, making it the first licensed therapy that uses the gene-editing tool CRISPR to help treat patients.

Manufacturing 52

Manufacturing In-Vivo Development Production 52

The Pharma Data

NOVEMBER 15, 2020

NASDAQ: ATHX), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Ms. 16, 2020 11:00 UTC. CLEVELAND–( BUSINESS WIRE )– Athersys, Inc. Katherine Kalin, Ms. Jane Wasman and Mr. Baiju R. Shah to its board of directors. About MultiStem ®. More information is available at www.athersys.com.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

MAY 4, 2021

Internal Medicine. billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., REVENUES. . . . . . ($ in millions). First-Quarter. . 1,611. . *. *. Inflammation & Immunology. Rare Disease.

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

JUNE 24, 2021

The production capacity has consistently grown due to continued enhancements to the vaccine’s supply chain, which include expanding existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52